DexCom was named a Barron’s stock pick in July. After DexCom shifted its focus to the Type 2 population last year, Type 1 sales constricted. However, the company looked ready to “recapture its losses, …
DexCom Stock Is the Worst Performer in the S&P 500. Here’s Why.
view original post